AORT

Business Context and Reporting Period

Company: CryoLife, Inc. (Note: Input metadata referenced "ARTIVION, INC." but the filing text identifies the registrant as CryoLife, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: CryoLife develops and commercializes biomaterials and medical devices, and preserves and distributes human tissues for cardiac and vascular transplant applications. Key products include BioGlue surgical adhesive, CryoValve SG pulmonary human heart valve, and tissue preservation services.

Key Financial Metrics

Revenue Breakdown (9 Months 2008):
- Preservation Services: $41,337 (52% of total)
- Products (primarily BioGlue): $37,499 (47% of total)
- Other: $691

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 21% for the quarter and 14% for the nine months ended September 30, 2008, compared to the prior year periods.
  • Preservation Services: Cardiac revenues rose 26% (quarter) and 26% (nine months), driven by the reintroduction of the CryoValve SG pulmonary heart valve and fee increases. Vascular revenues increased 36% (quarter) and 25% (nine months) due to higher unit shipments of saphenous veins. Orthopaedic revenues declined 93% (quarter) and 82% (nine months) following the cessation of marketing efforts per an agreement with Regeneration Technologies, Inc. (RTI).
  • Products: BioGlue revenues increased 13% for both periods, driven by favorable product mix (shift to syringes) and price increases.
• Profitability: Net income increased significantly, from $1,907 to $3,556 (quarter) and $4,552 to $10,209 (nine months). This was aided by reduced interest expense following the payoff of the Wells Fargo credit facility in February 2008 and the absence of the derivative valuation charge recorded in 2007.
• Costs: Cost of preservation services as a percentage of revenue improved (decreased) due to higher average service fees and lower tissue write-downs. Cost of products increased slightly as a percentage of revenue due to inventory write-downs of medical devices.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates continued revenue growth from CryoValve SG shipments and BioGlue. R&D spending is expected to exceed 2007 levels, focusing on BioFoam, BioDisc, and organ preservation. The company expects to utilize net operating loss carryforwards to offset 2008 taxable income.
• Liquidity: The company maintains a $15.0 million revolving credit facility with GE Capital. As of September 30, 2008, $5.0 million of cash is restricted as collateral under this agreement. Management believes existing cash and borrowing availability are sufficient for the next 12 months.
• Product Liability Risks: The company accrued $5.2 million for unreported product liability claims (estimated range up to $10.3 million). Of this, $1.7 million is estimated to be recoverable via insurance. One pending lawsuit regarding orthopaedic tissue is accrued at $330,000.
• Regulatory Risks: The company faces potential FDA actions regarding process validation and complaint handling. The CryoValve SG has a one-year shelf life (vs. five years for non-SynerGraft valves), creating inventory risk if not implanted in time.
• Unusual Items:
  • Derivative Liability: No derivative valuation charge in 2008, compared to an $821,000 charge in the nine months of 2007 related to preferred stock conversion.
  • Inventory Write-downs: $172,000 write-down of deferred preservation costs and $1.2 million write-down of medical device inventory in the nine months ended September 30, 2008.

Investor Verification Checklist

• Product Liability Exposure: Verify the accuracy of the $5.2 million actuarial accrual for unreported claims and the $1.7 million insurance recoverable estimate.
• CryoValve SG Performance: Monitor shipment volumes and fee retention for the CryoValve SG to ensure it continues to command a premium over standard valves.
• Shelf Life Constraints: Assess inventory levels of SynerGraft processed valves given the one-year shelf life limitation and potential for spoilage.
• Foreign Exchange Impact: Evaluate the sensitivity of BioGlue revenues (denominated in Euros and British Pounds) to currency fluctuations, which could materially impact Q4 2008 and 2009 results.
• Patent Litigation: Track the status of the German patent nullity action filed by Tenaxis, Inc. against CryoLife's BioGlue patent and CryoLife's counter-suit for infringement.
• Deferred Tax Assets: Monitor the company's ability to reverse the $28.2 million valuation allowance on deferred tax assets, which would result in a non-cash gain but increase future effective tax rates.